Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02749331

Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy

An open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Neuroendocrine Tumors Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Endocrine Oncology Clinic, Uppsala University Hospital

Uppsala, 752 37, Sweden

About this study

An open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose. Secondary objectives include to evaluate the anti-tumoral efficacy of AdVince infusions on metastatic neuroendocrine tumors, to determine the replication profile of AdVince and to determine the humoral (antibody) and cytokine-mediated immune response to AdVince. Minimum 12 and maximum 35 patients will be included, the number is based on the toxicity observed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject´s written informed consent
  • Histologically and radiologically confirmed progressive neuroendocrine carcinoma of gastrointestinal, pancreatic or bronchial origin with multiple liver metastases. Progression in Clinical symptoms and tumor growth verified over the last 6 months on CT or MRI
  • Cancer that is not considered resectable for potential cure or tumor reduction
  • Patent portal vein and adequate liver perfusion
  • Liver dominant disease with involvement of <60% of liver parenchyma
  • Karnofsky performance status of >=70%
  • Life expectancy of >=6 months
  • >=18 years of age
  • Must use a reliable method of contraception if sexually active and of reproductive potential
  • Plasma creatinine <105 ug/ml
  • Aspartate transaminase (AST), Alanine transaminase (ALT) and Alkaline Phosphatase (ALP) <3.0-fold upper limit of normal
  • Total bilirubin <2.0-fold upper limit of normal
  • Prothrombin time (PT)/International Normalized Ratio (INR) <2.0 and Prothromboplastin time (PTT) within normal limits
  • Neutrophils >1500/ml, hemoglobin >100 g/L, platelets >100 000/ml
  • Patients with functioning NET should have cover by somatostatin analog

Exclusion criteria

  • Known chronic liver dysfunction Before the development of metastatic cancer (e.g. cirrhosis, chronic hepatitis)
  • Active infection, including documented HIV and hepatitis C
  • Any viral syndrome diagnosed within the previous 2 weeks
  • Chemotherapy within the previous 4 weeks Before the first treatment
  • Radiotherapy to the target tumor site within the last 24 weeks from the baseline CT scan
  • Concomitant malignancy
  • Pregnant or lactating females
  • Prior participation in any research protocol that involved administration of adenovirus vectors
  • Treatment with any other investigational therapy within the last 4 weeks, organ transplantation prior to treatment, severe cardiovascular, metabolic or pulmonary disease
  • Continuing treatment with any other cancer therapy

Treatment and study plan

AdVince

Drug

Virus solution for infusion in intrahepatic artery

Other names: Ad5PeptideTransductionDomain(PTD)(CgA-E1AmiR122)

Primary outcomes

  1. Number of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03

    Time frame: From screening visit and through study completion, an average time of 18 months.

    AEs probably or possibly related to the study drug or local injuries caused by the administration procedure. If possible identify dose limiting toxicity (DLT), i.e. grade 4 toxicity of any duration or grade 3 toxicity lasting more than 7 days, excluding flu-like symptoms, according to CTCAE v4.03.Clinically significant changes in laboratory parameters (haematology, blood coagulation, liver function, biochemistry and kidney function) and vital signs (body temperature, heart rate, blood pressure, respiratory rate and consciousness according to Reaction Level Scale from 1985 (RLS-85).

Secondary outcomes

  1. Change in tumor size

    Time frame: Measured within 4 weeks before first treatment and after 80 +/-14 days (evaluation visit 1)

    Computer tomography (CT) and/or positron emission tomography (PET) with magnetic resonance imaging (MRI). Assessment based on Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST (mRECIST).

  2. Change in tumor size

    Time frame: Measured within 4 weeks before first treatment and after 214 +/- 14 days (evaluation visit 2)

    Computer tomography (CT) and/or positron emission tomography (PET) with magnetic resonance imaging (MRI). Assessment based on Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST (mRECIST).

  3. Change in tumor metabolic activity

    Time frame: Baseline value within 24 hrs before first treatment and after 80 +/- 14 days(evaluation visit 1)

    Change in hormone levels including chromogranin- A (CgA), chromogranin-B (CgB), neuron specific enolase (NSE) and specific hormones.

  4. Change in tumor metabolic activity

    Time frame: Baseline value within 24 hrs before first treatment and after 214 +/- 14 days (evaluation visit 2)

    Change in hormone levels including chromogranin- A (CgA), chromogranin-B (CgB), neuron specific enolase (NSE) and specific hormones.

  5. Progression-free survival (PFS)

    Time frame: Twelve weeks after 80 days from first treatment (4 treatment cycles) or the corresponding time.

    Number of patients with progression-free survival (PFS).

  6. Change in replication profile of AdVince

    Time frame: Before and 4hrs after each treatment cycle up to a time period of 214 days.

    Replication profile determined by quantification of adenovirus genomic copies in patient´s blood by quantitative real-time polymerase chain reaction (QRT-PCR).

  7. Change in replication profile of AdVince

    Time frame: Before and 24hrs after each treatment up to a time period of 214 days.

    Replication profile determined by quantification of adenovirus genomic copies in patient´s blood by quantitative real-time polymerase chain reaction (QRT-PCR).

  8. Change in replication profile of AdVince

    Time frame: Before and 72hrs after each treatment cycle up to a time period of 214 days.

    Replication profile determined by quantification of adenovirus genomic copies in patient´s blood by quantitative real-time polymerase chain reaction (QRT-PCR).

  9. Change in the humoral immune response to AdVince

    Time frame: At baseline, after 8+2 days, after 50 +/- 7days, optional after 124 +/- 7days and 184 +/- 7 days.

    Detection of anti-adenovirus neutralizing antibodies against adenovirus.

  10. Change in the cytokine-mediated immune response

    Time frame: At baseline and at 4hrs following each treatment up to a time period of 214 days.

    Measure from patient´s plasma.

  11. Change in the cytokine-mediated immune response

    Time frame: At baseline and at 24hrs following each treatment up to a time period of 214 days.

    Measure from patient´s plasma.

  12. Change in the cytokine-mediated immune response

    Time frame: At baseline and at 72hrs following each treatment up to a time period of 214 days.

    Measured from patient´s plasma.

Sponsors and collaborators

Lead sponsor

Uppsala University

Other

Registry information

Official study title

Study of Recombinant Adenovirus (AdVince) in Patients With Neuroendocrine Tumors; Safety and Efficacy

Acronym: RADNET

Important dates

Study start
2016
Primary completion
2025
Study completion
2025
First posted
Apr 22, 2016
Registry last updated
Dec 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.